Skip to content
TrialScanner

NCT04519567

Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Phase 1CompletedLRMRLead

Registry record

Lead sponsor
Larimar Therapeutics, Inc.
Conditions
Friedreich Ataxia
Primary completion
Mar 16, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04519567 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04519567: Multiple Ascending Dose... | TrialScanner